版本:
中国

BRIEF-Cancer Genetics partners with Ventana Medical Systems for market access to predictive biomarker test

May 15 Cancer Genetics Inc

* Cancer Genetics, Inc. Partners with Ventana Medical Systems, Inc., a member of the Roche Group, to ensure market access to predictive biomarker test for new immuno-oncology (io) therapy for advanced bladder cancer

* Cancer Genetics - partnered with Ventana Medical Systems to enable rapid patient access to testing following FDA's approval of Roche's Ventana PD-l1 assay Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐